Literature DB >> 28078272

Novel methods for the treatment of liver fibrosis using in vivo direct reprogramming technology.

Takeshi Goya1, Atsushi Suzuki2.   

Abstract

Entities:  

Year:  2016        PMID： 28078272      PMCID： PMC5222716          DOI： 10.21037/sci.2016.11.10

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN： 2306-9759


× No keyword cloud information.
  13 in total

1.  Differentiation and transplantation of human induced pluripotent stem cell-derived hepatocyte-like cells.

Authors:  Samira Asgari; Mohsen Moslem; Kamran Bagheri-Lankarani; Behshad Pournasr; Maryam Miryounesi; Hossein Baharvand
Journal:  Stem Cell Rev Rep       Date:  2013-08       Impact factor: 5.739

2.  Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors.

Authors:  Sayaka Sekiya; Atsushi Suzuki
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

3.  Direct Reprogramming of Hepatic Myofibroblasts into Hepatocytes In Vivo Attenuates Liver Fibrosis.

Authors:  Guangqi Song; Martin Pacher; Asha Balakrishnan; Qinggong Yuan; Hsin-Chieh Tsay; Dakai Yang; Julia Reetz; Sabine Brandes; Zhen Dai; Brigitte M Pützer; Marcos J Araúzo-Bravo; Doris Steinemann; Tom Luedde; Robert F Schwabe; Michael P Manns; Hans R Schöler; Axel Schambach; Tobias Cantz; Michael Ott; Amar Deep Sharma
Journal:  Cell Stem Cell       Date:  2016-02-25       Impact factor: 24.633

4.  In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins.

Authors:  Hua Liu; Yonghak Kim; Saul Sharkis; Luigi Marchionni; Yoon-Young Jang
Journal:  Sci Transl Med       Date:  2011-05-11       Impact factor: 17.956

5.  Small Molecules Facilitate Single Factor-Mediated Hepatic Reprogramming.

Authors:  Kyung Tae Lim; Seung Chan Lee; Yimeng Gao; Kee-Pyo Kim; Guangqi Song; Su Yeon An; Kenjiro Adachi; Yu Jin Jang; Jonghun Kim; Kyoung-Jin Oh; Tae Hwan Kwak; Seon In Hwang; Jueng Soo You; Kinarm Ko; Seung-Hoi Koo; Amar Deep Sharma; Jong-Hoon Kim; Lijian Hui; Tobias Cantz; Hans R Schöler; Dong Wook Han
Journal:  Cell Rep       Date:  2016-04-14       Impact factor: 9.423

6.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.

Authors:  Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote
Journal:  Lancet       Date:  2012-12-10       Impact factor: 79.321

7.  Direct reprogramming of human fibroblasts to functional and expandable hepatocytes.

Authors:  Pengyu Huang; Ludi Zhang; Yimeng Gao; Zhiying He; Dan Yao; Zhitao Wu; Jin Cen; Xiaotao Chen; Changcheng Liu; Yiping Hu; Dongmei Lai; Zhenlei Hu; Li Chen; Ying Zhang; Xin Cheng; Xiaojun Ma; Guoyu Pan; Xin Wang; Lijian Hui
Journal:  Cell Stem Cell       Date:  2014-02-27       Impact factor: 24.633

8.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  In Vivo Hepatic Reprogramming of Myofibroblasts with AAV Vectors as a Therapeutic Strategy for Liver Fibrosis.

Authors:  Milad Rezvani; Regina Español-Suñer; Yann Malato; Laure Dumont; Andrew A Grimm; Eike Kienle; Jay G Bindman; Ellen Wiedtke; Bernadette Y Hsu; Syed J Naqvi; Robert F Schwabe; Carlos U Corvera; Dirk Grimm; Holger Willenbring
Journal:  Cell Stem Cell       Date:  2016-06-02       Impact factor: 24.633

Review 10.  Potential of human induced pluripotent stem cells in studies of liver disease.

Authors:  Fotios Sampaziotis; Charis-Patricia Segeritz; Ludovic Vallier
Journal:  Hepatology       Date:  2015-02-10       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.